Press Releases

 
Press Releases
  Date Title and Summary View
Oct 17, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 17, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017, at 10:30 a.m. ET, to review the company's financial results for the third quarter ended Sept. 30, 2017. Mylan will release its financial results on Nov. 6,...
Oct 16, 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents relating to Restasis® invalid based on obviousness. The Court, recognizing that Al...
Oct 5, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that partner, Synthon, received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL, a therapeutically equivalent generic version of Teva's Copaxone® 40 mg/mL, indicated for the treatment of patien...
Oct 5, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the first AP-rated generic version of Bayer's Avelox®. The product is being marketed a...
Oct 4, 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone® 40 mg/mL, as well as Glatiramer Acetate ...
Oct 4, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is working to provide aid to those affected by Hurricanes Harvey, Irma and Maria in Florida, Puerto Rico and Texas. To date, the company has shipped more than 6 million doses of medicine, including anti-infective, cardiovascula...
Oct 3, 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 3, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection, an AP-rated, substitutable generic version of Teva...
Oct 2, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 2, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic versions of Merck's Cancidas®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...
Sep 29, 2017
HERTFORDSHIRE, England and PITTSBURGH, Sept. 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Imatinib Mesylate Tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Appli...
Sep 14, 2017
HERTFORDSHIRE, England and PITTSBURGH, Sept. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy (1).  Mylan's subsidiary, Mylan Laboratories Limited, re...
Page:
1
... NextLast
= add release to Briefcase